SCHEMBL2934528

SCHEMBL2934528

CC[C@H](OC(=O)Cl)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.44
LMNA P02545 3/20 0.44
CYP2D6 P10635 1/20 0.42
POLB P06746 1/20 0.41
MEN1 O00255 1/20 0.41
KLK7 P49862 1/20 0.41
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
ALDH1A1 P00352 2/20 0.40
PABPC1 P11940 1/20 0.40
APOBEC3A P31941 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KCNQ2 O43526 1/20 0.40
ALKBH1 Q13686 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CHRM2 P08172 1/20 0.39
CHRM4 P08173 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8158169 1.00 KMT2A (0.44) KMT2ALMNACYP2D6POLBMEN1
SCHEMBL2936559 1.00 KMT2A (0.44) KMT2ALMNACYP2D6POLBMEN1
SCHEMBL11212738 0.86 AOC3 (0.44) KMT2ACYP2D6POLBSMN1; SMN2
SCHEMBL983637 0.85 LMNA (0.47) KMT2ALMNAPOLBMEN1KLK7
SCHEMBL6665775 0.85 LMNA (0.47) KMT2ALMNAPOLBMEN1KLK7
SCHEMBL648756 0.85 LMNA (0.47) KMT2ALMNACYP2D6POLBMEN1
SCHEMBL9608808 0.83 PABPC1 (0.55) KMT2ALMNAPOLBMEN1KLK7
SCHEMBL2294116 0.83 PABPC1 (0.55) KMT2ALMNAPOLBMEN1KLK7
SCHEMBL664962 0.83 PABPC1 (0.55) KMT2ALMNAPOLBMEN1KLK7
SCHEMBL8678282 0.83 LMNA (0.45) KMT2ALMNAPOLBMEN1KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD KMT2A 3722/4885LMNA 2796/4885CYP2D6 490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.